SAN MATEO, Calif., May 16, 2011 /PRNewswire/ -- On April 28, 2011 the New England Journal of Medicine released highly anticipated one-year results of the ongoing "Comparisons of Age-Related Macular Degeneration Treatments Trials" (CATT).
AlphaDetail, Inc., a leader in global ophthalmology primary market research and influence network mapping, has conducted its latest AlphaPulse™ survey with 120 Ophthalmologists to gauge their reactions on the heels of this important news.
Amy Tsang, a Director at AlphaDetail, explained, "The use of Avastin vs. Lucentis in Wet AMD has been debated among eye care professionals for years, and many anticipated that these results could bring closure to the issue."
While results from the trial confirmed that Avastin is non-inferior to Lucentis on visual acuity efficacy measures, the results related to level of risk associated with serious adverse events are less definitive.
To learn more about this study and to receive full results, please contact Amy Tsang at Amy.Tsang@alphadetail.com or (650) 581-3127.
About AlphaDetail, Inc.:
At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our clients' most challenging questions.
|SOURCE AlphaDetail, Inc.|
Copyright©2010 PR Newswire.
All rights reserved